MX2021013447A - Composiciones y procedimientos para el tratamiento de enfermedades oculares. - Google Patents

Composiciones y procedimientos para el tratamiento de enfermedades oculares.

Info

Publication number
MX2021013447A
MX2021013447A MX2021013447A MX2021013447A MX2021013447A MX 2021013447 A MX2021013447 A MX 2021013447A MX 2021013447 A MX2021013447 A MX 2021013447A MX 2021013447 A MX2021013447 A MX 2021013447A MX 2021013447 A MX2021013447 A MX 2021013447A
Authority
MX
Mexico
Prior art keywords
compositions
methods
ocular diseases
treatment
disclosure relates
Prior art date
Application number
MX2021013447A
Other languages
English (en)
Spanish (es)
Inventor
Brenda K Mann
Hee - Kyoung Lee
Original Assignee
Eyegate Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eyegate Pharmaceuticals Inc filed Critical Eyegate Pharmaceuticals Inc
Publication of MX2021013447A publication Critical patent/MX2021013447A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2021013447A 2019-05-03 2020-04-30 Composiciones y procedimientos para el tratamiento de enfermedades oculares. MX2021013447A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962842995P 2019-05-03 2019-05-03
PCT/US2020/030691 WO2020227002A1 (en) 2019-05-03 2020-04-30 Compositions and methods for treatment of ocular diseases

Publications (1)

Publication Number Publication Date
MX2021013447A true MX2021013447A (es) 2022-02-11

Family

ID=70861542

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021013447A MX2021013447A (es) 2019-05-03 2020-04-30 Composiciones y procedimientos para el tratamiento de enfermedades oculares.

Country Status (9)

Country Link
US (2) US11376214B2 (enExample)
EP (1) EP3962452A1 (enExample)
JP (1) JP7334266B2 (enExample)
KR (2) KR102649858B1 (enExample)
CN (1) CN114025742A (enExample)
CA (1) CA3139060A1 (enExample)
IL (1) IL287802B2 (enExample)
MX (1) MX2021013447A (enExample)
WO (1) WO2020227002A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10945858B2 (en) * 2010-09-03 2021-03-16 Globus Medical, Inc. Expandable interspinous process fixation device
GB202008857D0 (en) * 2020-06-11 2020-07-29 Univ Birmingham Fluid gel compositions
GB202008853D0 (en) * 2020-06-11 2020-07-29 Univ Birmingham Fluid gel compositions
CN112587475B (zh) * 2020-12-18 2022-09-13 华熙生物科技股份有限公司 一种载药凝胶及其制备方法
DE102023116924A1 (de) * 2023-06-27 2025-01-02 Carl Zeiss Meditec Ag Kit zur Verwendung in einer Augenoperation und ophthalmische viskoelastische Vorrichtung
WO2025155730A1 (en) * 2024-01-16 2025-07-24 Regents Of The University Of Minnesota Injectable hydrogel for embolization

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1368309B2 (en) * 2001-02-22 2014-10-01 Anika Therapeutics Inc. Thiol-modified hyaluronan
CA2703807C (en) * 2010-05-12 2017-10-24 Molly S. Shoichet Enhanced stability of inverse thermal gelling composite hydrogels
US10137199B2 (en) * 2013-05-14 2018-11-27 Biotime, Inc. Thiolated hyaluronan-based hydrogels cross-linked using oxidized glutathione
US9782345B2 (en) * 2013-10-17 2017-10-10 Jade Therapeutics, Inc. Ocular composition and method
EP3675873A4 (en) 2017-09-01 2021-06-16 Pmidg, Llc Functionalized and crosslinked polymers
CN118126415A (zh) 2017-09-19 2024-06-04 香港科技大学 生物可相容材料以及用于制备和使用所述生物可相容材料的方法

Also Published As

Publication number Publication date
CA3139060A1 (en) 2020-11-12
US20220287961A1 (en) 2022-09-15
KR20240038152A (ko) 2024-03-22
EP3962452A1 (en) 2022-03-09
IL287802B1 (en) 2024-05-01
US11376214B2 (en) 2022-07-05
US20200345634A1 (en) 2020-11-05
KR20220004753A (ko) 2022-01-11
IL287802A (en) 2022-01-01
CN114025742A (zh) 2022-02-08
KR102649858B1 (ko) 2024-03-20
WO2020227002A1 (en) 2020-11-12
JP2022530837A (ja) 2022-07-01
JP7334266B2 (ja) 2023-08-28
IL287802B2 (en) 2024-09-01

Similar Documents

Publication Publication Date Title
MX2020001340A (es) Modelos celulares y terapias para enfermedades oculares.
MX2020006128A (es) Inhibidores de la proteina de activacion de fibroblastos.
PH12021550621A1 (en) Ophthalmic compositions for treatment of ocular surface damage and symptoms of dryness
PH12020551427A1 (en) Epinephrine spray formulations
EP4566651A3 (en) Ophthalmic delivery device
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
EP4616902A3 (en) Nerve stimulation for treating migraine and other headache conditions
BR112018005318A2 (pt) ?polipeptídeos de lisina ativos contra bactérias gram-negativas?
EP4324454A3 (en) Cross-linking agents and associated methods
MX2022000310A (es) Inhibidores de proteina bcl-2.
MX2021010058A (es) Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel.
WO2019209948A8 (en) Compounds and uses thereof
MX2021004755A (es) Uso de plasma y fracciones de plasma para mejorar el dolor, la cicatrizacion de heridas y la recuperacion posoperatoria.
BR112017015387A2 (pt) composição em gel tópica, método de tratamento de uma infecção da pele, composição em gel oftálmica, e, método de tratamento de uma afecção infecciosa do olho ou pálpebra
AU2018236629A8 (en) Hydrogel patch
WO2018208793A8 (en) S-NITROSOGLUTATHIOME INHIBITORS (GSNO) AND GSNO REDUCTASE USEFUL IN THERAPY
EP4378535A3 (en) Antibiotic formulations for lower back pain
WO2023064278A3 (en) Compositions and methods that inhibit il-23 signaling
EP4582446A3 (en) Methods of treating al amyloidosis
MX2021004819A (es) Composiciones y metodos para tratar lesiones cerebrales.
GB2541840A (en) Ophthalmic composition for the treatment of ocular infection
EP4556060A3 (en) Treatment of acute medical conditions
EP4417259A3 (en) Compositions and methods for prevention and treatment of corneal haze and scarring
WO2020219823A8 (en) Intracanalicular hydrogel inserts for the delivery of anesthetics
WO2019099860A3 (en) Wound treatment containing collagen and a gelatin-reducing agent, and method for promoting wound healing